{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '117 Avenue de Luminy',
 'address2': 'BP 30191',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.53,
 'askSize': 1800,
 'averageDailyVolume10Day': 3887,
 'averageVolume': 8269,
 'averageVolume10days': 3887,
 'beta': -0.175581,
 'beta3Year': None,
 'bid': 6.39,
 'bidSize': 1800,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Marseille',
 'companyOfficers': [],
 'country': 'France',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 6.4,
 'dayLow': 6.36,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 501212800,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 6.3546286,
 'fiftyTwoWeekHigh': 8.24,
 'fiftyTwoWeekLow': 3.3,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 48514406,
 'forwardEps': 0.45,
 'forwardPE': 14.222223,
 'fromCurrency': None,
 'fullTimeEmployees': 235,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01559,
 'heldPercentInstitutions': 0.09909,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/innate-pharma.com',
 'longBusinessSummary': 'Innate Pharma S.A., a biotechnology company, '
                        'discovers and develops therapeutic antibodies for the '
                        'treatment of oncology indications in France and '
                        "internationally. The company's products include "
                        'Monalizumab, an immune checkpoint inhibitor that is '
                        'in Phase II clinical trial to treat advanced solid '
                        'tumors comprising colorectal cancer, as well as head '
                        'and neck cancer; Anti-Siglec-9, checkpoint inhibitor '
                        'program, which is in preclinical stage for '
                        'immuno-oncology; Lumoxiti (moxetumomab '
                        'pasudotox-tdfk), a tumor antigen targeting solution '
                        'for the treatment of hairy cell leukemia; and '
                        'Lacutamab (IPH4102), an anti-KIR3DL2 humanized '
                        'cytotoxicity-inducing antibody, which is in Phase II '
                        'clinical trial for the treatment of cutaneous T-cell '
                        'lymphoma. Its products also include IPH61, a '
                        'bispecific NK cell engager, a preclinical solution '
                        'for the generation and evaluation of up to two '
                        'bispecific NK cell engagers; IPH43, a program that is '
                        'in preclinical trial to develop anti-MICA/B '
                        'therapeutic antibody in oncology; '
                        'Avdoralimab/IPH5401, a therapeutic antibody, which is '
                        'in Phase II clinical trial that binds and blocks C5a '
                        'receptors expressed on subsets of myeloid-derived '
                        'suppressor cells and neutrophils; IPH5201, a blocking '
                        'antibody that is in Phase I clinical trial targeting '
                        'the CD39 immunosuppressive pathway; and IPH5301, a '
                        'CD-73-blocking antibody that is in preclinical trial '
                        'for restoring a pro-inflammatory microenvironment. '
                        'Innate Pharma S.A. has licensing and collaboration '
                        'agreements with AstraZeneca, Novo Nordisk A/S, and '
                        'Sanofi; and co-development and license agreement with '
                        'MedImmune. The company was founded in 1999 and is '
                        'headquartered in Marseille, France.',
 'longName': 'Innate Pharma S.A.',
 'market': 'us_market',
 'marketCap': 498737248,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_426137',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1577750400,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 6.3822,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '33 4 30 30 30 30',
 'previousClose': 6.42,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': -0.24191,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 6.4,
 'regularMarketDayLow': 6.36,
 'regularMarketOpen': 6.3822,
 'regularMarketPreviousClose': 6.42,
 'regularMarketPrice': 6.3822,
 'regularMarketVolume': 1527,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 78879696,
 'sharesPercentSharesOut': 0.0002,
 'sharesShort': 13851,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 18208,
 'shortName': 'Innate Pharma S.A.',
 'shortPercentOfFloat': None,
 'shortRatio': 2.25,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'IPHA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 6.657705,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '95b2a86c-03b1-3402-a4e5-5bdc8b44e164',
 'volume': 1527,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.innate-pharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '13009'}